BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
43 hedge funds and large institutions have $6.16M invested in BRAINSTORM CELL THERAPUTC in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 4 closing their positions.
552% more call options, than puts
Call options by funds: $847K | Put options by funds: $130K
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
2% more funds holding
Funds holding: 42 → 43 (+1)
0.03% less ownership
Funds ownership: 0.71% → 0.67% (-0.03%)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
64% less capital invested
Capital invested by funds: $17.1M → $6.16M (-$11M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$264K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$61.2K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$42.3K |
| 4 |
Jane Street
New York
|
+$35K |
| 5 |
SCFS
S.C. Financial Services
Scottsdale,
Arizona
|
+$31.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$254K |
| 2 |
Renaissance Technologies
New York
|
-$109K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$80K |
| 4 |
CCMW
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
|
-$71K |
| 5 |
WCG
Weaver Consulting Group
Huntington Beach,
California
|
-$69.9K |
BCLI Hedge Fund Activity: Q4 2022 in Review
43 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2022, worth a combined $6.16M — down 64% from $17.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BCLI positions and 4 closed out — a net gain of 3 holders — while 7 added to existing stakes and 11 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $264K. The largest seller was Millennium Management, cutting an estimated $254K.
- 43 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2022, up from 42 in Q3 2022.
- Funds reported $6.16M of BRAINSTORM CELL THERAPUTC stock for Q4 2022, down 64% quarter-over-quarter.
- 7 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2022 and 4 closed out, a net change of +3 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2022 was Susquehanna International Group, an estimated $264K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2022 was Millennium Management, an estimated $254K sold.
Based on aggregated 13F filings for Q4 2022.